| 6.035 -0.065 (-1.07%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.4 | 1-year : | 8.64 |
| Resists | First : | 6.34 | Second : | 7.4 |
| Pivot price | 5.89 |
|||
| Supports | First : | 5.82 | Second : | 5.5 |
| MAs | MA(5) : | 5.95 |
MA(20) : | 5.87  |
| MA(100) : | 6.38 |
MA(250) : | 6.67 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 68.7 |
D(3) : | 54.1 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 9.63 | Low : | 5.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CSBR ] has closed below upper band by 27.3%. Bollinger Bands are 40.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.09 - 6.13 | 6.13 - 6.16 |
| Low: | 5.88 - 5.92 | 5.92 - 5.96 |
| Close: | 5.96 - 6.03 | 6.03 - 6.1 |
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Fri, 10 Apr 2026
CSBR Should I Buy - Intellectia AI
Thu, 09 Apr 2026
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026 - ACCESS Newswire
Thu, 09 Apr 2026
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026 - The Batesville Daily Guard
Thu, 09 Apr 2026
Eight cancer studies from Champions Oncology focus on drug response, resistance - Stock Titan
Wed, 01 Apr 2026
CSBR PE Ratio & Valuation, Is CSBR Overvalued - Intellectia AI
Mon, 30 Mar 2026
Brian Alexander joins Champions Oncology (NASDAQ: CSBR) board - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 26.6 (%) |
| Held by Institutions | 47.8 (%) |
| Shares Short | 73 (K) |
| Shares Short P.Month | 75 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | -4.1 % |
| Operating Margin | -1.2 % |
| Return on Assets (ttm) | -4.7 % |
| Return on Equity (ttm) | -47.6 % |
| Qtrly Rev. Growth | -2.8 % |
| Gross Profit (p.s.) | 1.91 |
| Sales Per Share | 4.17 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | -33.53 |
| PEG Ratio | 0 |
| Price to Book value | 19.46 |
| Price to Sales | 1.44 |
| Price to Cash Flow | 19.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|